Recursion Q3 revenue misses estimates, net loss widens

Recursion Pharmaceuticals

05/11/2025 11:39

Overview

Recursion Q3 operating revenue misses analyst expectations

Net loss for Q3 widens, missing analyst estimates

Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Outlook

Recursion expects cash runway to extend through 2027 without additional financing

Company anticipates over $100 mln in milestone payments by end of 2026

Result Drivers

MILESTONE PAYMENT - Achieved $30 mln milestone from Roche and Genentech for microglial immune cells map

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Operating Revenue
Miss
$4.98 mln
$17 mln (6 Analysts)
Q3 Net Income
Miss
-$162.25 mln
-$146.90 mln (3 Analysts)
Q3 Pretax Profit
Miss
-$162.25 mln
-$128.90 mln (1 Analyst)
Q3 Operating Income
-$172.20 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is $6.50, about 23.1% above its November 4 closing price of $5.00

Press Release: ID:nGNXgQ3S5

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)